Posted by Michael Wonder on 20 Sep 2024
BioCryst and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Orladeyo (berotralstat), an oral, once daily therapy for the prevention of hereditary angioedema attacks
17 September 2024 - BioCryst Pharmaceuticals today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for oral, once daily Orladeyo (berotralstat), which is approved in Canada for the routine prevention of attacks of hereditary angioedema in adults and paediatric patients 12 years of age and older.
Orladeyo was approved by Health Canada in June 2022.
